The treatment of liver cirrhosis – currently based on symptomatic management of complications – has barely changed in last 20 years. In this episode, the experts discuss the use of statins, for which there is growing body of evidence of their beneficial effects in patients suffering with cirrhosis.

Faculty

• Thomas Reiberger (Moderator)
• Juan Gonzalez-Abraldes (Faculty)
• Elisa Pose (Faculty)
• Jonel Trebicka (Faculty)

This EASL Studio is supported by Boehringer Ingelheim. EASL has received no input from Boehringer Ingelheim with regards to the content of this programme.

Related episodes

• EASL Studio from EASL Congress 2023: Liver cirrhosis in 2023: Unmet needs and how to address them
• EASL Studio S4E17: Albumin in Cirrhosis: For all, some, or none?
• EASL Studio S4E4: JHEP Live: is the term ‘decompensated cirrhosis’ outdated?
• EASL Studio S3E12: Meeting the challenge of antimicrobial resistance (AMR) in cirrhosis: the invisible threat that lies within

All EASL Studio Podcasts are available on EASL Campus.